Clinical trial / 1997
In patients with moderate Alzheimer's disease, alpha-tocopherol or selegiline significantly delayed progression to primary disease endpoints in adjusted analyses.
A 2-year randomized trial assigned 341 patients with moderate Alzheimer's disease to receive selegiline (10 mg/day), alpha-tocopherol (vitamin E, 2000 IU/day), both, or placebo. In unadjusted analyses, there was no statistically significant difference in outcomes among the four groups. After adjusting for baseline Mini-Mental State Examination scores, significant delays in time to the primary outcome were observed for selegiline (median 655 days, P=0.012), alpha-tocopherol (median 670 days, P=0.001), and combination therapy (median 585 days, P=0.049) compared with placebo (median 440 days).
- Study type
- Double-blind, placebo-controlled, randomized multicenter trial
- Who was studied
- 341 patients with Alzheimer's disease of moderate severity
- What was measured
- Time to death, institutionalization, loss of ability to perform basic activities of daily living, or severe dementia
THE PAPER
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. N Engl J Med, 1997.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.